公开(公告)号：EP4269402A1

公开(公告)日：2023-11-01

申请号：EP21908644.4

申请日：2021-08-27

申请人： GT Apeiron Therapeutics Limited ,  Exscientia Al Limited

发明人： GU, Xiaohui ,  BAI, Haiyun ,  BARBEAU, Olivier Rémy ,  BESNARD, Jérémy

IPC分类号： C07D401/14 ,  C07D401/00 ,  A61K31/506 ,  A61K31/505 ,  A61K31/495 ,  C07D471/04 ,  C07D413/14 ,  C07D417/14 ,  A61P35/00

摘要： An aromatic heterocyclic compound, a pharmaceutical composition and use thereof. Specifically disclosed are a compound as shown in formula I, a stereoisomer thereof, a diastereomer thereof, or a pharmaceutically acceptable salt of any one of the foregoing, or a crystal form or solvate of any one of the foregoing. The aromatic heterocyclic compound has a novel structure, good CDK7 inhibitory activity, and good selectivity.

公开(公告)号：EP4269403A1

公开(公告)日：2023-11-01

申请号：EP21908645.1

申请日：2021-08-27

申请人： GT Apeiron Therapeutics Limited ,  Exscientia Al Limited

发明人： GU, Xiaohui ,  BAI, Haiyun ,  BARBEAU, Olivier Rémy ,  BESNARD, Jérémy

IPC分类号： C07D401/14 ,  C07D401/00 ,  A61K31/506 ,  A61K31/505 ,  A61K31/495 ,  C07D471/04 ,  A61P35/00

摘要： An aromatic heterocyclic compound, and a pharmaceutical composition and an application thereof. Specifically disclosed are a compound as represented by formula I-A, a stereoisomer thereof, a diastereoisomer thereof, or a pharmaceutically acceptable salt of any one of the described substances, or a crystalline form or a solvate of any one of the described substances. The aromatic heterocyclic compound is novel in structure, and has good CDK7 inhibitory activity and good selectivity.

公开(公告)号：EP4105935A1

公开(公告)日：2022-12-21

申请号：EP22162348.1

申请日：2010-11-22

申请人： Exscientia Al Limited

发明人： BESNARD, Jérémy ,  HOPKINS, Andrew, Lee

IPC分类号： G16C20/50 ,  G16C20/70

摘要： A method for computational drug design using an evolutionary algorithm, comprises evaluating virtual molecules according to vector distance (VD) to at least one achievement objective that defines a desired ideal molecule. In one method the invention comprises defining a set of n achievement objectives (O A 1-n ), where n is at least one; defining a population (P G=0 ) of at least one molecule; selecting an initial population (P parent ) of at least one molecule (I 1 -I n ) from the population (P G=0 ); and evaluating members (I 1 -I n ) of the initial population (P parent ) against at least one of the n achievement objectives (O A 1-x ), where x is from 1 to n.